DSM successfully completes secondary offering of shares in Patheon N.V.
(Thomson Reuters ONE) -
Royal DSM, a global science-based company active in health, nutrition and
materials, today announces the successful completion of its secondary offering
of 4,761,905 ordinary shares in Patheon N.V. in connection with Patheon N.V.'s
Initial Public Offering of ordinary shares. The total cash proceeds for DSM from
the secondary offering and the transactions related to the IPO are expected to
amount to approximately $240 million.
DSM now holds approximately 48.7 million ordinary shares, or approximately 34%
of Patheon N.V., with approximately 43% held by affiliates of JLL Partners and
Patheon N.V.'s management team and 23% free float.
Total cash proceeds for DSM are expected to amount to approximately $240
million, consisting of net proceeds of approximately $95 million from the
secondary offering and an expected $145 million in dividend distributions and
capital repayments related to the IPO.
DSM expects to realize a book profit of approximately ?220m, which will be
reported as part of DSM's Q3 2016 results, while any potential future gains on
disposal of the remaining shares held in Patheon N.V., if any, will be
recognized at the time of any such transaction(s). Patheon N.V. did not receive
any proceeds from the sale of ordinary shares by DSM.
Copies of the final prospectus relating to the offering were filed with the U.S.
Securities and Exchange Commission ("SEC") on 22 July 2016 and may be obtained
from:
J. P. Morgan Securities LLC
c/o Broadridge Financial Solutions
1155 Long Island Avenue
Edgewood, New York 11717
Attn: Prospectus Group
Telephone: (866) 803-9204
Morgan Stanley & Co. LLC
180 Varick Street, Second Floor
New York, New York 10014
Attn: Prospectus Department
Jefferies LLC
520 Madison Avenue, 2nd Floor
New York, New York 10022
Attn: Equity Syndicate Prospectus Department
Email: Prospectus_Department(at)Jefferies.com
Telephone: (877) 547-6340
UBS Securities LLC
1285 Avenue of the Americas
New York, New York 10019
Attn: Prospectus Department
Telephone: (888) 827-7275
A registration statement relating to these securities has been filed with, and
was declared effective on 20 July 2016 by, the SEC. The offering of these
securities is being made only by means of a written prospectus forming part of
the effective registration statement. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
The statements in this press release that are not historical facts may be
forward-looking statements. Such forward looking statements, based upon current
beliefs and expectations, are subject to risks and uncertainties, which could
cause actual results to differ from the forward looking statements. Accordingly,
readers should not place undue reliance on forward-looking statements as a
prediction of actual results. For more information concerning factors that could
cause actual results to differ materially from those conveyed in the forward-
looking statements, please refer to the "Risk Factors" section of the prospectus
included in the registration statement, in the form last filed with the SEC. DSM
does not assume any obligation to update the information contained in this press
release.
This press release may contain forward-looking statements with respect to DSM's
future (financial) performance and position. Such statements are based on
current expectations, estimates and projections of DSM and information currently
available to the company. DSM cautions readers that such statements involve
certain risks and uncertainties that are difficult to predict and therefore it
should be understood that many factors can cause actual performance and position
to differ materially from these statements. DSM has no obligation to update the
statements contained in this press release, unless required by law. The English
language version of the press release is leading.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in life sciences and materials
sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders simultaneously. DSM
delivers innovative solutions that nourish, protect and improve performance in
global markets such as food and dietary supplements, personal care, feed,
medical devices, automotive, paints, electrical and electronics, life
protection, alternative energy and bio-based materials. DSM and its associated
companies deliver annual net sales of about ?10 billion with approximately
25,000 employees. The company is listed on Euronext Amsterdam. More information
can be found at www.dsm.com.
For more information:
DSM Corporate Communications DSM Investor Relations
Stephen Hufton Dave Huizing
tel. +31 (0) 45 5787029 tel. +31 (0) 45 5782864
e-mail media.contacts(at)dsm.com e-mail investor.relations(at)dsm.com
Press release-pdf:
http://hugin.info/130663/R/2030800/755450.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via GlobeNewswire
[HUG#2030800]
Unternehmensinformation / Kurzprofil:
Datum: 27.07.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 485588
Anzahl Zeichen: 6504
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM successfully completes secondary offering of shares in Patheon N.V."
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
